Fri, Aug 1, 2014, 8:49 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Pharmacyclics Inc. Message Board

  • searanch919 searanch919 Jun 4, 2012 12:09 PM Flag

    Updated Results

    powerful stuff:

    "Overall response rate in the 420 mg cohort is 81% using ibrutinib as a single agent. 12% of patients achieved a complete response with no morphologic evidence of CLL. Progression free survival with a median follow-up of 14.4 months is 96% in the 420 mg cohort."

116.91-3.53(-2.93%)Aug 1 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.